Subtopic Deep Dive
Bacterial Lysates for Preventing Recurrent Respiratory Infections
Research Guide
What is Bacterial Lysates for Preventing Recurrent Respiratory Infections?
Bacterial lysates are polyvalent immunostimulants derived from inactivated bacteria used to prevent recurrent respiratory tract infections (RTIs) in pediatric populations, particularly daycare children.
Randomized trials evaluate their immunogenicity, efficacy against RTIs, and safety in children. OM-85 BV, a specific lysate, showed no primary preventive effect in a 2020 double-blind placebo-controlled pilot study by Pinto et al. (11 citations). Research spans 2016-2022 with 87 total citations across four key papers.
Why It Matters
Bacterial lysates offer non-antibiotic prophylaxis amid rising antimicrobial resistance, supporting antibiotic stewardship in pediatrics. Pinto et al. (2020) tested OM-85 BV for primary prevention of RTIs in children, finding no efficacy but highlighting need for trials in recurrent cases. Papadopoulos et al. (2017, 61 citations) outline lysate approaches for viral respiratory illnesses, reducing emergency visits as noted in Grandinetti et al. (2022, 15 citations) where preschool wheezers double ED access rates. Legg (2016) discusses immunomodulation perspectives for recurrent RTIs.
Key Research Challenges
Efficacy in Primary Prevention
Trials like Pinto et al. (2020) show OM-85 BV ineffective for primary RTI prevention in children. More randomized studies needed for daycare cohorts. Safety profiles require long-term pediatric data.
Immunogenicity Mechanisms
Understanding lysate-induced immune responses against specific pathogens remains unclear. Papadopoulos et al. (2017) highlight promising approaches but lack detailed mechanisms. Pediatric variability complicates immunogenicity assessment.
Risk Factor Integration
Integrating lysates with wheezing risk factors is challenging, as per Grandinetti et al. (2022). Preschool wheeze affects 30% of children under three, doubling ED visits. Tailoring to high-risk groups needs consensus.
Essential Papers
Promising approaches for the treatment and prevention of viral respiratory illnesses
Nikolaos G. Papadopoulos, Spyridon Megremis, Nikolaos A. Kitsioulis et al. · 2017 · Journal of Allergy and Clinical Immunology · 61 citations
Risk Factors Affecting Development and Persistence of Preschool Wheezing: Consensus Document of the Emilia-Romagna Asthma (ERA) Study Group
Roberto Grandinetti, Valentina Fainardi, Carlo Caffarelli et al. · 2022 · Journal of Clinical Medicine · 15 citations
Wheezing at preschool age (i.e., before the age of six) is common, occurring in about 30% of children before the age of three. In terms of health care burden, preschool children with wheeze show do...
OM-85 BV for primary prevention of recurrent airway infections: a pilot randomized, double-blind, placebo-controlled study
Fátima Cleonice de Souza, Magáli Mocellin, Renata Ongaratto et al. · 2020 · Einstein (São Paulo) · 11 citations
OM-85 BV was not effective in the primary prevention of respiratory tract infections. Although most authors recommend the use of this immunostimulant in children with a history of recurrent respira...
Immunomodulation for Recurrent Respiratory Tract Infections: New Insights and Perspectives
Ewen Legg · 2016 · EMJ Respiratory · 0 citations
The 1st biennial WAidid Congress held in Milan, Italy, brought together academics and clinicians from the broad field of infectious diseases and immunology. The conference was founded in order to c...
Reading Guide
Foundational Papers
No pre-2015 foundational papers available; start with Legg (2016) for immunomodulation perspectives as baseline.
Recent Advances
Pinto et al. (2020) for OM-85 BV trial data; Grandinetti et al. (2022) for preschool wheezing risks; Papadopoulos et al. (2017) for prevention approaches.
Core Methods
Randomized double-blind placebo-controlled trials (Pinto et al., 2020); risk factor consensus analysis (Grandinetti et al., 2022); literature reviews on immunostimulants (Legg, 2016).
How PapersFlow Helps You Research Bacterial Lysates for Preventing Recurrent Respiratory Infections
Discover & Search
Research Agent uses searchPapers and exaSearch to find trials on bacterial lysates like OM-85 BV, then citationGraph on Pinto et al. (2020) reveals 11 citing papers on RTI prevention. findSimilarPapers expands to Papadopoulos et al. (2017) for viral approaches.
Analyze & Verify
Analysis Agent applies readPaperContent to extract OM-85 BV trial outcomes from Pinto et al. (2020), then verifyResponse with CoVe checks claims against Grandinetti et al. (2022). runPythonAnalysis with pandas computes GRADE evidence grades for RTI reduction efficacy across studies; statistical verification tests recurrence rate differences.
Synthesize & Write
Synthesis Agent detects gaps in primary vs. recurrent RTI efficacy from Pinto et al. (2020) and Legg (2016), flagging contradictions. Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 87-citation bibliography, and latexCompile for report; exportMermaid diagrams immunostimulant pathways.
Use Cases
"Run meta-analysis on OM-85 BV recurrence rates in daycare kids using Python."
Research Agent → searchPapers('OM-85 BV recurrent RTIs') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on Pinto et al. 2020 + similar papers) → researcher gets CSV of pooled odds ratios and forest plot.
"Draft LaTeX review on bacterial lysates for preschool wheezing prevention."
Synthesis Agent → gap detection(Legg 2016 + Grandinetti 2022) → Writing Agent → latexEditText(structured review) → latexSyncCitations(Papadopoulos 2017) → latexCompile → researcher gets PDF with cited sections and figures.
"Find code for RTI risk factor models from related papers."
Research Agent → paperExtractUrls(Grandinetti 2022) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for preschool wheeze prediction models.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(250M+ via OpenAlex for 'bacterial lysates RTIs pediatrics') → citationGraph → GRADE grading → structured report on 50+ papers like Pinto et al. DeepScan applies 7-step analysis with CoVe checkpoints to verify OM-85 efficacy claims. Theorizer generates hypotheses on lysate dosing from Legg (2016) immunomodulation insights.
Frequently Asked Questions
What are bacterial lysates in RTI prevention?
Polyvalent immunostimulants from inactivated bacteria, like OM-85 BV, used to reduce recurrent RTIs in children (Pinto et al., 2020).
What methods are used in key studies?
Randomized double-blind placebo-controlled trials, as in Pinto et al. (2020) pilot for primary prevention; consensus on risk factors in Grandinetti et al. (2022).
What are key papers?
Papadopoulos et al. (2017, 61 citations) on viral prevention; Pinto et al. (2020, 11 citations) on OM-85 BV; Grandinetti et al. (2022, 15 citations) on wheezing risks.
What open problems exist?
Efficacy in primary vs. recurrent RTIs unclear (Pinto et al., 2020); need mechanistic studies and long-term safety data in pediatrics (Legg, 2016).
Research Pediatric health and respiratory diseases with AI
PapersFlow provides specialized AI tools for Health Professions researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bacterial Lysates for Preventing Recurrent Respiratory Infections with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Health Professions researchers